Natera (NASDAQ:NTRA) Insider John Fesko Sells 339 Shares

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 339 shares of the stock in a transaction dated Wednesday, January 21st. The shares were sold at an average price of $235.00, for a total transaction of $79,665.00. Following the transaction, the insider owned 177,252 shares of the company’s stock, valued at approximately $41,654,220. The trade was a 0.19% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

John Fesko also recently made the following trade(s):

• On Tuesday, January 20th, John Fesko sold 17,806 shares of Natera stock. The stock was sold at an average price of $234.74, for a total transaction of $4,179,780.44.
• On Tuesday, October 28th, John Fesko sold 928 shares of Natera stock. The shares were sold at an average price of $191.46, for a total value of $177,674.88.
• On Monday, October 27th, John Fesko sold 781 shares of Natera stock. The stock was sold at an average price of $192.32, for a total value of $150,201.92.

Natera Price Performance

Shares of NASDAQ NTRA opened at $242.91 on Friday. The stock has a market capitalization of $33.60 billion, a PE ratio of -106.07 and a beta of 1.62. Natera, Inc. has a one year low of $125.38 and a one year high of $256.36. The business’s fifty day moving average price is $233.44 and its 200-day moving average price is $190.60.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Friday, November 7th. The medical research company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The business had revenue of $592.18 million for the quarter, compared to analysts’ expectations of $514.55 million. Natera had a negative net margin of 14.61% and a negative return on equity of 25.07%. Natera’s revenue for the quarter was up 34.7% compared to the same quarter last year. During the same period last year, the company earned ($0.26) earnings per share. As a group, equities analysts expect that Natera, Inc. will post -1.49 EPS for the current fiscal year.

Analyst Ratings Changes

NTRA has been the topic of several recent research reports. Barclays increased their target price on Natera from $230.00 to $270.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. BNP Paribas Exane upgraded Natera to a “hold” rating and set a $172.00 price target on the stock in a research report on Monday, October 27th. UBS Group raised their price objective on shares of Natera from $218.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, November 18th. Stephens upped their target price on shares of Natera from $197.00 to $235.00 and gave the stock an “overweight” rating in a report on Thursday, November 13th. Finally, Guggenheim raised their price target on shares of Natera from $230.00 to $270.00 and gave the company a “buy” rating in a report on Monday, January 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $245.50.

Institutional Trading of Natera

A number of hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. increased its stake in Natera by 2.3% in the second quarter. Vanguard Group Inc. now owns 12,676,653 shares of the medical research company’s stock valued at $2,141,594,000 after acquiring an additional 282,826 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in shares of Natera by 9.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock worth $1,871,914,000 after purchasing an additional 1,003,129 shares in the last quarter. State Street Corp increased its position in shares of Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after purchasing an additional 72,087 shares during the last quarter. Franklin Resources Inc. raised its holdings in shares of Natera by 37.5% during the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after buying an additional 727,366 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Natera by 7.0% in the 2nd quarter. Geode Capital Management LLC now owns 2,552,725 shares of the medical research company’s stock worth $430,640,000 after buying an additional 166,768 shares during the last quarter. 99.90% of the stock is owned by institutional investors.

Trending Headlines about Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Natera published peer‑reviewed clinical validation of its Latitude™ tissue‑free MRD test for colorectal cancer in npj Precision Oncology, strengthening clinical credibility for a higher‑value oncology product that could support future revenue/coverage expansion. Clinical validation article
• Positive Sentiment: Multiple sell‑side analysts have raised price targets (examples: Barclays, JPMorgan, Guggenheim) and the consensus remains a “Moderate Buy” with a MarketBeat implied target around $245.50 — bullish support for the stock’s medium‑term outlook.
• Neutral Sentiment: Institutional ownership is extremely high (~99.9%), and recent quarter revenue growth was strong (revenue up ~34.7% YoY), but profitability remains negative — factors that can both support and cap near‑term moves depending on execution and sentiment.
• Negative Sentiment: CEO Steven Chapman executed a large sale on Jan. 20 (71,932 shares, ~$16.9M at ~$234.74) and additional smaller sales on Jan. 21 — a material reduction in his stake that markets often interpret as negative signal. CEO Form 4
• Negative Sentiment: CFO Michael Burkes Brophy sold large blocks across Jan. 20–21 (23,948 and 37,175 shares), cutting his ownership materially — another significant insider liquidation that increases perceived supply and can pressure the stock. CFO Form 4
• Negative Sentiment: Other insiders (John Fesko, Solomon Moshkevich) also sold sizable positions (tens of thousands of shares combined) on Jan. 20–21 — the clustered timing of multiple insider sales magnifies negative investor perception. Insider Form 4 example

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.